Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1 and GIP), which enhance insulin secretion and suppress glucagon release in a glucose-dependent manner.
## Primary Indications
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
## Adult Dosing
* **Standard Dose:** 5 mg orally once daily.
* **Maximum Dose:** 5 mg daily.
## Pediatric Dosing
Safety and efficacy have not been established in patients younger than 18 years. Use is not recommended.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment required.
* **Hepatic Impairment:** No dosage adjustment required.
## Contraindications
* History of hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with sulfonylureas or insulin).
* **Serious/Rare:** Acute pancreatitis, bullous pemphigoid, severe arthralgia, hypersensitivity reactions.
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., rifampin):** May decrease linagliptin exposure. Consider alternative agents if glycemic control is inadequate.
* **Insulin/Insulin Secretagogues:** Risk of hypoglycemia may be increased; dose reduction of the secretagogue or insulin may be required.
## Monitoring
* **HbA1c:** Typically every 3–6 months.
* **Glucose:** Self-monitoring of blood glucose (SMBG) if indicated by therapy (e.g., concomitant insulin).
* **Clinical:** Monitor for signs of pancreatitis (persistent severe abdominal pain) and bullous skin lesions.
## Clinical Pearls
* Linagliptin is unique among DPP-4 inhibitors as its primary route of excretion is non-renal (biliary/GI tract); therefore, no dose adjustment is needed for any stage of renal impairment.
* Can be taken with or without food.
* Does not cause meaningful weight gain and has a low intrinsic risk of hypoglycemia when used as monotherapy.
* Discontinue agent if pancreatitis or bullous pemphigoid is suspected.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice protocols may vary by institution. Always consult the latest FDA-approved prescribing information or institutional clinical guidelines before prescribing or administering medications.
